CJC-1295 with DAC
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC
Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.
Benefits
6
Conditions
5
Evidence
Clinical trials, pharmacokinetic studies+ studies
Source
Synthetic GHRH analog with drug affinity complex
Gabriel Brain Score
Moderate
Overview
Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.
Mechanism of Action
GHRH analog with DAC modification binding to albumin for extended half-life (6-8 days), provides sustained GH and IGF-1 elevation, mimics continuous GHRH stimulation rather than pulsatile.
Key Benefits
- ✓Long-lasting GH elevation (one injection per week)
- ✓Sustained IGF-1 increase
- ✓Convenience of infrequent dosing
- ✓Muscle growth support
- ✓Improved recovery
- ✓Body composition benefits
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Clinical trials, pharmacokinetic studies
Clinical evidence for sustained GH and IGF-1 elevation. Provides continuous rather than pulsatile GH release, which may be less physiologic than modified GRF (CJC-1295 no DAC).
Safety Information
Potential Side Effects
- •Water retention
- •Increased hunger
- •Numbness/tingling
- •Headache
- •Fatigue
Contraindications
- Active cancer
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
Interactions
- ⚠May affect glucose metabolism
Quick Facts
Related Peptides
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Hexarelin
Potent hexapeptide ghrelin mimetic with strong GH-releasing effects and cardioprotective properties.
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.